Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial
Reuters2026/09/09 06:46- Elicera Therapeutics will advance ELC-301 into Phase IIa in its CARMA study in B-cell lymphoma, using the highest tested dose.
- The trial’s safety panel backed the dose selection with no major safety issues reported in the completed Phase I portion.
- Earlier interim results were already presented, showing broad disease control with many patients achieving tumor shrinkage, including some reaching disease-free status.
- The company plans to present preliminary Phase I efficacy results for all 12 patients once the last patient completes a one-month assessment.
- Phase IIa dosing is expected to start once Sweden’s Medical Products Agency clears the protocol to proceed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
